Literature DB >> 9663712

Hyperfibrinogenolysis in disseminated adenocarcinoma.

K Meijer1, W M Smid, S Geerards, J van der Meer.   

Abstract

We present the case of a 42-year-old woman with a recently acquired bleeding tendency. Coagulation studies and response to antifibrinolytic therapy suggested primary hyperfibrinogenolysis: markedly low levels of fibrinogen and alpha2-antiplasmin, normal levels of antithrombin III, protein C and protein S combined with an only borderline low number of platelets without evidence of microangiopathic haemolytic anaemia. A suspected causative adenocarcinoma of the lung was demonstrated. She was treated successfully with tranexamic acid and cryoprecipitate, until the tumor progressed and hyperfibrinogenolysis progressed to diffuse intravascular coagulation. Differential diagnosis of these coagulation disorders, with similar etiology, clinical and laboratory findings is reviewed. Therapeutic implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663712     DOI: 10.1097/00001721-199804000-00010

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Dynamic functional clot formation in patients undergoing endoscopic mucosal resection.

Authors:  Bernd Froessler; Leonardo Zorron Cheng Tao Pu; Natalie Aboustate; Amanda Ovenden; Rajvinder Singh
Journal:  JGH Open       Date:  2020-02-06

Review 2.  Successful thrombolytic therapy for acute kidney injury secondary to thrombosis of suprarenal inferior vena cava filter.

Authors:  Azra Bihorac; Craig S Kitchens
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

3.  Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.

Authors:  Michael Schwameis; Andreas Schober; Christian Schörgenhofer; Wolfgang Reinhard Sperr; Herbert Schöchl; Karin Janata-Schwatczek; Erol Istepan Kürkciyan; Fritz Sterz; Bernd Jilma
Journal:  Crit Care Med       Date:  2015-11       Impact factor: 7.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.